Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

被引：16
|
作者：
Scagliotti, Giorgio
Purvish, Parikh
von Pawel, Joachim
Biesma, Bonna
Vansteenkiste, Johan
Manegold, Christian
Simms, Lorinda
Posther, Sugarman Katherine
Obasaju, Coleman
Blatter, Johannes
机构：
[1] Univ Turin, S Luigi Hosp, Orbassano, Italy
[2] Tata Mem Hosp, Bombay, Maharashtra, India
[3] Asklepios Fachklin Munchen, Munich, Germany
[4] Jeroen Bosch Ziekenhuis, sHertogenbosch, Netherlands
[5] Univ Hosp Gasthuisberg, Louvain, Belgium
[6] Heidelberg Univ, Med Ctr, Mannheim, Germany
[7] Eli Lilly Canada, Toronto, ON, Canada
[8] Eli Lilly & Co, Indianapolis, IN USA
[9] Eli Lilly, Bad Homburg, Germany
来源：
JOURNAL OF THORACIC ONCOLOGY | 2007年 / 2卷 / 08期
关键词：
D O I：
10.1097/01.JTO.0000283088.78970.9b
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S306 / S306
页数：1
相关论文
共 50 条
  • [41] Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III randomized trial
    Georgoulias, V
    Ardavanis, A
    Tsiafaki, X
    Agelidou, A
    Mixalopoulou, P
    Anagnostopoulou, O
    Ziotopoulos, P
    Toubis, M
    Syrigos, K
    Samaras, N
    Polyzos, A
    Christou, A
    Kakolyris, S
    Kouroussis, C
    Androulakis, N
    Samonis, G
    Chatzidaki, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) : 2937 - 2945
  • [42] Analysis of the costs of bevacizumab plus cisplatin and gemcitabine versus cetuximab plus vinorelbine and cisplatin in patients with advanced non-small cell lung cancer (NSCLC) in France: Results from a cost modelling study
    Chouaid, C.
    Vergnenegre, A.
    Florentin, V.
    Walzer, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] Analysis of cost-effectiveness of Bevacizumab plus cisplatin and gemcitabine (BCG) compared to an induction therapy with pemetrexed plus cisplatin (PC) in advanced or recurrent non-small cell lung cancer (NSCLC)
    Bischoff, H.
    Heigener, D.
    Wiesner, C.
    Walzer, S.
    [J]. ONKOLOGIE, 2010, 33 : 131 - 132
  • [44] A COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH PEMETREXED PLUS CISPLATIN (PC) FOR THE TREATMENT OF ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY
    Bischoff, H. G.
    Heigener, D.
    Wiesner, C.
    Walzer, S.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A273 - A273
  • [45] FIRST LINE CHEMOTHERAPY WITH PEMETREXED PLUS CISPLATIN IN ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A COMPARISON OF TWO PHASE III TRIALS
    Scagliotti, Giorgio
    Gridelli, Cesare
    De Marinis, Filippo
    Thomas, Michael
    Dedui, Mircea
    Pujol, Jean-Louis
    Manegold, Christian
    Melemed, Symantha
    John, William
    Zimmermann, Annamaria H.
    Chouaki, Nadia
    Melemed, Allen
    Visseren-Grul, Carla
    Paz Ares, Luis
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1160 - S1161
  • [46] An indirect comparison of the efficacy of bevacizumab plus cisplatin and gemcitabine (BCG) or bevacizumab plus carboplatin and paclitaxel (BCP) versus pemetrexed plus cisplatin (PC) and cetuximab plus vinorelbine and cisplatin (CVC) in patients (pts) with advanced or recurrent non-small cell cancer (NSCLC)
    Walzer, S.
    de Castro Carpeno, J.
    Vergnenegre, A. V.
    Chouaid, C.
    Heigener, D. F. H.
    Bischoff, H. G.
    Nicolson, M. C.
    Aultman, R.
    Siebert, U.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 555 - 555
  • [47] Gemcitabin (G) plus cisplatin (P) versus etoposid (E) plus cisplatin in advanced/metastatic non-small cell lung cancer (NSCLC): Preliminary results of a randomized monocentric study
    Bousahba, A.
    Bereksi-Reguig, F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [48] A cost analysis of treatment with bevacizumab plus cisplatin and gemcitabine (BCG) versus cetuximab plus vinorelbine and cisplatin (CVC) in patients with advanced or recurrent non-small cell lung cancer (NSCLC) in Germany
    Heigener, D. F.
    Wiesner, C.
    Aultman, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] Cisplatin plus vinorelbine or gemcitabine in patients with advanced non-small cell lung cancer: Pharmacoeconomic considerations
    Hughes, DA
    [J]. EUROPEAN JOURNAL OF CANCER, 2005, 41 (11) : 1655 - 1655
  • [50] Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
    Ohe, Y.
    Ohashi, Y.
    Kubota, K.
    Tamura, T.
    Nakagawa, K.
    Negoro, S.
    Nishiwaki, Y.
    Saijo, N.
    Ariyoshi, Y.
    Fukuoka, M.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (02) : 317 - 323
12345